The in vitro diagnostics company had a lot of bad news in its Q4 update.
/PRNewswire/ -- In an inspiring and emotional display of solidarity for Lyme disease awareness, a striking public service announcement (PSA) has taken center...
Despite solid performances by the Labs segment and China region, QuidelOrtho (QDEL) reports soft overall top-line results in first-quarter 2023.
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 28.57% and 0.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and...
QuidelOrtho's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued strength in its non-respiratory product sales.
QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
It looks like the company's first quarter is going to please investors greatly.
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and...
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine,...